Log in
Enquire now
Novartis

Novartis

Novartis is a healthcare and pharmaceutical company based in Basel, Switzerland, incorporated in 1996.

OverviewStructured DataIssuesContributors

Contents

novartis.co.jp
pharma.us.novartis.com
novartis.es
novartis.com
zolgensma.com
...
Is a
Investor
Investor
Company
Company
Organization
Organization
Product
Product

Company attributes

Industry
Immunotherapy
Immunotherapy
Pharmaceutical industry
Pharmaceutical industry
0
Biopharmaceutical
Biopharmaceutical
Drug discovery
Drug discovery
0
Medical diagnostics
Medical diagnostics
0
RNA
RNA
Biomedical engineering
Biomedical engineering
Chemical industry
Chemical industry
...
Location
Tokyo
Tokyo
San Francisco
San Francisco
Parsippany-Troy Hills, New Jersey
Parsippany-Troy Hills, New Jersey
‌
East Hanover Township, New Jersey
Lincoln, Nebraska
Lincoln, Nebraska
Emeryville, California
Emeryville, California
San Diego
San Diego
Duluth, Georgia
Duluth, Georgia
...
B2X
B2C
B2C
0
B2B
B2B
CEO
Vas Narasimhan
Vas Narasimhan
Joe Jimenez
Joe Jimenez
Founder
Daniel Vasella
Daniel Vasella
‌
Joerg Reinhardt
AngelList URL
angel.co/novartis
Pitchbook URL
pitchbook.com/profiles.../42001-39
Legal Name
Novartis International AG
Parent Organization
Sandoz
Sandoz
Novartis
Novartis
Subsidiary
Novartis
Novartis
‌
Chiron Corporation
Novartis Venture Fund
Novartis Venture Fund
Lek (pharmaceutical company)
Lek (pharmaceutical company)
Sandoz
Sandoz
Novartis Healthcare Organization
Novartis Healthcare Organization
Alcon
Alcon
Legal classification
Public limited company
Public limited company
Aktiengesellschaft
Aktiengesellschaft
Spinout
Eyevensys
Eyevensys
Number of Employees (Ranges)
10,001+
Email Address
media.relations@novartis.com0
eric.althoff@novartis.com
Phone Number
+817955640000
+177047639370
+813689980000
+161787180000
+176026862000
+416132411110
+130346624000
+186277821000
...
Number of Employees
119,418
Full Address
Novartis Campus Basel, Baselstadt 4002, CH0
CIK Number
1,114,448
Place of Incorporation
Basel
Basel
Investors
Cormorant Asset Management
Cormorant Asset Management
Janus Henderson Investors
Janus Henderson Investors
RA Capital Management
RA Capital Management
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
Access Biotechnology
Access Biotechnology
Bios Partners
Bios Partners
0
Logos Capital
Logos Capital
Viva BioInnovator
Viva BioInnovator
...
Founded Date
1996
Fax Number
+41 61 324 80010
+1 303 438 44740
+1 617 871 77880
+1 760 268 62010
+81 3 6257 36340
+81 79 556 40300
Total Funding Amount (USD)
106,500,000
Latest Funding Round Date
March 5, 2021
Competitors
Vero Biotech
Vero Biotech
IXICO
IXICO
‌
Salix Pharmaceuticals
Business Model
Commerce
Stock Symbol
NOVN0
NVS0
Exchange
New York Stock Exchange
New York Stock Exchange
0
SIX Swiss Exchange
SIX Swiss Exchange
Glassdoor ID
6667
Board of Directors
‌
Nancy Andrews
0
‌
Simon Moroney
0
‌
Ton Buechner
0
‌
Joerg Reinhardt
0
‌
Charlotte Pamer-Wieser
0
‌
William T. Winters
0
Charles Sawyers
Charles Sawyers
0
Frans van Houten
Frans van Houten
0
...
CFO
‌
Harry Kirsch
Former CEO
Paul Hudson
Paul Hudson
Joe Jimenez
Joe Jimenez
Daniel Vasella
Daniel Vasella
Key People
Vas Narasimhan
Vas Narasimhan
‌
Steffen Lang
‌
Joerg Reinhardt
0
James E. Bradner
James E. Bradner
‌
Harry Kirsch
0
‌
Rob Kowalski
0
Acquisition Transaction
‌
Acquisition of DTx Pharma by Novartis
Also Known As
Novartis International AG
DTx Pharma
Zolgensma
Latest Funding Type
Series B
Series B
NAICS Code
325,412
CAGE Code
04520
Patents Assigned (Count)
2,986
Legal Entity Identifier
5493007HIVTX6SY6XD660
COO
‌
Rob Kowalski
Motto/Tagline
No pipelines, just pipedreams
Wellfound ID
novartis
Technologies Used
CRISPR
CRISPR
Country
Switzerland
Switzerland
0
United States
United States
0
Japan
Japan
0
Headquarters
Basel
Basel
0

Investor attributes

Invested in
Aktis Oncology
Aktis Oncology
Roche Pharmaceuticals
Roche Pharmaceuticals
Ayala Pharmaceuticals
Ayala Pharmaceuticals
‌
Cota Healthcare
Dunad Therapeutics
Dunad Therapeutics
‌
SiO2 Medical Products, Inc.
‌
Anaeropharma Science
‌
Raze Therapeutics
...

Other attributes

Company Operating Status
Active
Strategic Partnerships
Incyte
Incyte
Contact Page URL
novartis.com/contacts
Founder of
‌
Lincoln Snacks Company
0
Syngenta Group
Syngenta Group
Latest Funding Round Amount (USD)
100,000,000
6,500,000
Market Capitalization
172,750,000,000
Owner
Wasabröd
Wasabröd
Owner of
‌
Sandoz factory Orléans
Sandoz
Sandoz
Partner Organizations
‌
Wok digital
Previous Name
Sandoz AG
CIBA
Ciba-Geigy
Geigy Ltd.
Public/Private
Public0
Ticker Symbol
NVS
Wikidata ID
Q507154

Novartis products include oncology medicines, generic and biosimilar medicines and eye care devices. The Innovative Medicine segment of the company is divided into Novartis Oncology and Novartis Pharmaceuticals. Novartis Pharmaceuticals consists of global business franchises in ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic and established medicines.

Divisions
Novartis Oncology

Novartis Oncology is focused on the development and manufacturing of medicines directed towards improving and extending people's lives.

Sandoz

Sandoz is a division of Novartis that manufactures, distributes and sells prescription medicines and pharmaceutical active substances that are not patent protected and is franchised into Retail generics, Anti-Infectives and Biopharmaceuticals.

Alcon

Alcon is a division of Novartis in the eye car product field in eye care devices and vision care. Alcon’s surgical franchise includes technologies and devices for cataract, retinal, glaucoma and refractive surgery and intraocular lenses to treat cataracts and refractive errors. Alcon’s Vision Care franchise includes contact lenses and contact lens care products. Alcon’s surgical portfolio also includes equipment for performing cataract surgery.

Novartis Gene Therapies

Previously known as AveXis, Novartis Gene Therapies works to develop and commercialize gene therapies. They have a specific focus on neurological genetic diseases. Their initial gene therapy is for spinal muscular atrophy and has been approved in the United States, Japan, the European Union, and Brazil.

Novartis Institutes for BioMedical Research (NIBR)

Part of their research and development program, the Novartis Institutes for BioMedical Research (NIBR) is working on developing informatics tools for drug discovery with a focus on open-sourced software.

Habitat

Habitat is a software developed to be a self-contained object storage management system. Based on Amazon Web Services, Novartis says Habitat is capable of virtually unlimited storage and can be used as a local repository for a single application or shared and used with many clients.

Yet Another Data Abstraction (YADA)

Novartis says Yet Another Data Abstraction (YADA) is a data aggregation tool capable of accessing data sets at any data source in any format and from any environment with a single URL and a single configuration. YADA is intended to be a lightweight framework for data retrieval, searching, storage, and manipulation.

OntoBrowser

OntoBrowser is a web-based application for managing ontologies. Developed by Novartis, they say the tool is intended to provide an online collaborative solution for curators to map code list terms to preferred ontology terms. OntoBrowser also offers visualization of ontologies in hierarchical or graph format, advanced search capabilities, and web service access to data.

Railroadtracks

Railroadtracks is a Python package Novartis says is intended to handle connected computation steps for DNA and RNA sequencing.

Yet Another Pipeline (YAP)

Yet Another Pipeline (YAP) is an extensible parallel framework developed by Novartis and written in Python using OpenMPI libraries. The software is intended to help researchers build high throughput data pipelines without knowledge of parallel programming.

RDKit

Developed by Novartis, the RDKit is a collection of cheminformatics and machine-learning softwre written in C++ and Python. The distribution includes a PostgreSQL-based cartridge allowing molecules to be stored in a relational database and allowing users to retrieve information via substructure and similarity searches.

GridVar

GridVar is a JQuery plugin that visualized multi-dimensional datasets as layers organized in a row-column format. Novartis says the software is intended to allow users to visualize data as a background color and enables characteristics of a dataset to be layered on top of each other.

Nerve Live

Developed by Novartis to use big data and data analytics, Nerve Live is an advanced analytics platform is intended to be used as part of a drug discovery program. Novartis sees the platform as enabling machine learning and cognitive computing systems to extract information which traditional data analysts and users might miss.

The Nerve Live was developed by first building a data lake. This was followed by developing an analytics engine to process the data and derive assets from it. And the final stage of development of this program involved designing user modules that would make predictive analytic insights and offer these insights to add value in business decisions.

Novartis hopes to develop Nerve Live to offer features to help manage resources, including using predictive models to plan medical supplies for medical centers.

data42 Program

The data42 program is a digital research and development platform Novartis believes will help in drug discovery and drug testing while costing less. The program would include large pools of patient and pharmaceutical data and an artificial intelligence to assist researchers in their development. As of March 2020, the program was still in the initial phases of development.

Research
Gleevec

Novartis, previously called Ciba-Geigy, was one of the few pharmaceutical companies involved in tyrosine kinase inhibitor research when it began a collaboration with oncologist Brian Druker which resulted in discovery of the kinase inhibitor drug Gleevec (also known as Glivec or imatinib). Gleevec was FDA approved in 2001 to treat patients with chronic myelogenous leukemia (CML). Kinases perform phosphorylation, a mechanism that controls the activity of proteins in the cell. CML patients have a mutation causing their tyrosine kinase to be overactive, which signals cell to proliferate at a high rate, resulting in accumulation of immature white blood cells. Based on revenue, Gleevec was one of Novartis’s top ten pharmaceutical products in 2017.

Kisqali

Novartis Oncology drug Kisqali (ribociclib) in Phase III MONALEESA (Mammary Oncology Assessment of LEE011’s (Ribociclib’s) Efficacy and Safety) trials, was reported in December 2018 to demonstrate efficacy and tolerability in combination with endocrine therapy in advanced breast cancer patients with visceral involvement. Kisqali (ribociclib) is a cyclin-dependent kinase inhibitor that inhibits cyclin-dependent kinase 4 and 6 (CDK4/6), proteins that when over active can promote cancer cell division and cancer growth. The drug is an orally available small molecule that acts by blocking phosphorylation of the retinoblastoma protein, which prevents cell-cycle progression. Kisqali is also in the NATALEE study, a Phase III clinical trial with endocrine therapy to treat early breast cancer.

ZOLGENSMA® (onasemnogene abeparvovec-xioi) is a gene therapy approved by the US Food and Drug Administration (FDA) for children less than 2 years old with spinal muscular atrophy (SMA).

ZOLGENSMA is given as a one-time infusion into a vein.

ZOLGENSMA was not evaluated in patients with advanced SMA.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

25 Years of Novartis - Continuing our innovation journey

https://youtu.be/UG40Ipneh8I

Web

March 2, 2021

Democratizing access to AI

https://youtu.be/gkkqHHPA5X0

Web

November 18, 2021

Drug development gets big data analytics boost

Goran Mijuk

https://www.novartis.com/stories/discovery/drug-development-gets-big-data-analytics-boost

Web

July 2, 2018

Novartis Financial Results Q1 2021

https://youtu.be/PubK49J9ll8

Web

April 26, 2021

The data42 program shows Novartis' intent to go big on data and digital

Goran Mijuk

https://www.novartis.com/stories/discovery/data42-program-shows-novartis-intent-go-big-data-and-digital

Web

March 11, 2020

References

Find more companies like Novartis

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.